Prostate Cancer Support Federation
Registered Charity Nº: 112337

20 Hallcroft Avenue
Countesthorpe
Leicester, LE8 5SL

Tel: 0116 277 5330
Email: treasurer@prostatecancerfederation.org.uk

Tuesday, 17 December, 2013

Meindert Boysen
Programme Director,
Centre for Health Technology Evaluation

Dear Meindert

Single Technology Appraisal (STA) – Enzalutamide for the treatment of metastatic hormone relapsed prostate cancer previously treated with a docetaxel-containing regimen [ID600]

The Prostate Cancer Support Federation welcomes the draft recommendation for the above STA. In particular, we are pleased to see that the grossly unfair caveat that enzalutamide cannot be given after abiraterone has been overruled. We hope that the CDF will follow your draft recommendation for the remaining time that this will be the only way to access enzaulamide.

Listed in the side affects are bone fractures and as both Dr. Simon Russell I and pointed out at the meeting, these awful events could be greatly reduced if bisphosphonates or denosumab were part of the recommended treatment pathway for advanced prostate cancer.

Yours sincerely

[redacted]
Hon. Treasurer
Prostate Cancer Support Federation

Prostate Cancer Support Federation